PTC Therapeutics at cantor healthcare conference: sephience drives growth
On Friday, 11 September 2026, PTC Therapeutics (PTCT) showcased its rare disease strategy at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. CEO Matt Klein and CFO Pierre Gravier highlighted the rapid launch of SEPHIENCE in PKU and progress across the pipeline. They acknowledged launch risks but also emphasized the company's growing momentum.
SEPHIENCE, or sepiapterin, is driving near-term revenue, while several development programs offer longer-term upside. The company aims to reach cash flow breakeven in 2026 and has more than $2 billion in cash reserves. PTC's balance sheet is a key strength, providing financial flexibility for multiple programs and strategic acquisitions.
SEPHIENCE has exceeded investor expectations and shows no signs of slowing. The launch was facilitated by pent-up demand and a patient population that is easier to identify compared to other rare diseases. About 2,500 patients remain on Kuvan, offering a switching opportunity. SEPHIENCE has shown improvement in phenylalanine lowering, diet liberalization, and benefits such as mental clarity, less brain fog, and reduced fatigue.
It is expected to be commercially available in Europe, the Middle East, Russia, the Commonwealth of Independent States, Latin America, and Canada in 2027 and beyond.
PTC also highlighted votoplam, its oral Huntington's disease program. Phase 2 data indicated a 52% slowing of disease progression at 24 months in higher-dose Stage 2 patients. A Phase 3 trial is underway with an enrollment target of about 770 people, focusing on a possible accelerated approval pathway with the FDA. PTC believes the therapy could benefit early-stage and genetically diagnosed pre-symptomatic patients as well.
The company's oral small-molecule splicing platform has expanded beyond previous targets, with the MSH3 program beginning about 3.5 years ago. PTC anticipates closing the acquisition of Sangamo Therapeutics' ST-920 program for Fabry disease within one to two weeks, contingent on a $111 million upfront payment. The splicing platform is expected to yield new programs, and ST-920 could become a significant commercial product in Fabry disease if regulatory approval is achieved.
PTC's financial outlook includes reaching cash flow breakeven in 2026, positioning the company for future deals while preserving flexibility.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
